NCT04794517View on ClinicalTrials.gov

Dapagliflozin in Non-diabetic Stage IV CKD

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

May 7, 2024

Study Completion Date

May 7, 2024

Conditions
Chronic Kidney Diseases
Interventions
DRUG

Dapagliflozin 10Mg Tab

Dapagliflozin 10 mg/die will be administered orally for six-weeks.

OTHER

Placebo

Placebo one tablet/die will be administered orally for six-weeks.

Trial Locations (1)

24020

"Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò", Ranica

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Mario Negri Institute for Pharmacological Research

OTHER